Abstract
BackgroundTocilizumab (TCZ) is the first humanised monoclonal antibody that targets and inhibits the human interleukin-6 receptor. The ACT-RAY study proved the clinical efficacy and safety of adding TCZ to MTX...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
